Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy
Posted inOncology Specialties

Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements in functional outcomes and fatigue management.
Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials
Posted inPsychiatry Specialties

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials

A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use disorder treatment.
Preoperative Cardiovascular Risk Does Not Alter Outcomes of Renin-Angiotensin System Inhibitor Use Before Major Noncardiac Surgery: Insights from a Secondary Analysis of the STOP-or-NOT Trial
Posted inCardiology Clinical Updates General Surgery Specialties

Preoperative Cardiovascular Risk Does Not Alter Outcomes of Renin-Angiotensin System Inhibitor Use Before Major Noncardiac Surgery: Insights from a Secondary Analysis of the STOP-or-NOT Trial

A secondary analysis of the STOP-or-NOT trial shows that preoperative cardiovascular risk stratification does not impact postoperative outcomes related to continuing or discontinuing renin-angiotensin system inhibitors before major noncardiac surgery.